← Back to Search

Cancer Vaccine

Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs) for Melanoma

Phase 1

Waitlist Available

Led By James Young, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is being done to see if the investigators can help the immune system to work against melanoma by using dendritic cells.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

safety

toxicity

Secondary outcome measures

immunogenicity

Trial Design

1Treatment groups

Experimental Treatment

Group I: vaccineExperimental Treatment1 Intervention

This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)

2011

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,933 Previous Clinical Trials

585,611 Total Patients Enrolled

76 Trials studying Melanoma

15,969 Patients Enrolled for Melanoma

Rockefeller UniversityOTHER

158 Previous Clinical Trials

16,348 Total Patients Enrolled

3 Trials studying Melanoma

192 Patients Enrolled for Melanoma

James Young, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

1 Previous Clinical Trials

43 Total Patients Enrolled

1 Trials studying Melanoma

43 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can administering Langerhans-type dendritic cells (LCs) provoke any adverse reactions in patients?

"The safety of Langerhans-type dendritic cells has been assessed as a 1 on our scale, due to the fact that this is a Phase 1 trial and there is minimal data regarding its efficacy or safety."

Answered by AI

Is recruitment still ongoing for this research project?

"Data hosted on clinicaltrials.gov indicates that applicants are not being sought for this trial, which was first posted October 17th 2011 and modified January 21st 2022. Nevertheless, there are currently 753 other medical studies actively recruiting participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

2011. "Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01456104.